Summary:
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild to Moderate Alzheimer’s Disease
Qualified Participants Must:
• Be 55 and 85 years old
•
Be diagnosed with mild to moderate Alzheimer's disease
•
Additional criteria apply
Qualified Participants May Receive:
Up to $750 for time and travel.